Healthcare Ad Restrictions Need Their Own TSA PreCheck

If you’ve traveled by plane recently, you know the drill: shoes off, liquids in a bag, step into the scanner. Each rule got added for a reason, at a different moment, in response to a real threat. Individually they made sense. Cumulatively they turned a simple process into an obstacle course. Now add AI-driven scanners that flag the one flimsy razor blade you forgot in your carry-on, and you’re off to the side while someone combs through your toiletries (hey, it happens!).

Healthcare advertising is following that arc. Restrictions layered on one at a time, each one makes sense on its own, until the system as a whole becomes difficult to navigate — especially now that AI is doing the scanning and false flags are piling up faster than anyone can appeal them.

The good news: like the travelers who figured out PreCheck, packed smarter, and planned ahead, marketers can adapt. First it helps to understand how we got here.

What marketers used to do, and what got taken away

The targeting capabilities healthcare marketers relied on weren’t removed all at once. They were plucked off gradually, each change arriving with a policy update or a regulatory nudge, until one day the foundation you’d built your programs on was mostly gone.

Condition-adjacent interest targeting used to let marketers reach users based on specific health interests: diabetes management apps, cardiology content, oncology support groups. Those granular categories have since collapsed into broad buckets under more general categories like “Health and Wellness,” which makes it more challenging to narrow in on your target for clinical or condition-specific campaigns. Where you once had a scalpel, you now have a sledgehammer.

Pixel-based retargeting went next. In the summer of 2022, Meta removed pixel retargeting for health and wellness advertisers following regulatory pressure from the Department of Health and Human Services and growing concerns about HIPAA exposure. The pixel had been the backbone of lower-funnel healthcare campaigns, and it was effectively off the table.

Lookalike audiences followed the same path. Lookalike modeling lets marketers take website visitor data and find similar users at scale. Meta has since restricted the use of health-related custom audiences as seeds for lookalikes, gutting the mechanism that made this work. These are permanent architectural changes, the kind a compliance review can’t fix.

LinkedIn Insight Tag retargeting was next. LinkedIn brought its own Insight Tag restrictions to healthcare domains, collapsing the retargeting pool and conversion tracking that made B2B healthcare professional campaigns measurable.

Lower-funnel conversion events took the latest hit. Even where some targeting remains available, platforms have restricted the conversion events healthcare advertisers can optimize toward, pushing campaigns toward awareness objectives on platforms where full-funnel programs used to run.

Meta has typically been first to introduce these restrictions, with other platforms following its lead. This isn’t unique to healthcare, either. Specialty ad categories have shown up across finance, employment, housing, and elections, driven by the same mix of FTC scrutiny, state privacy legislation, and platform risk aversion. Healthcare is just the most visible case right now, and the one where the stakes are highest.

What’s happening now, and why it feels different

The earlier wave of restrictions was painful but navigable. What’s happening now feels different because it is. AI has changed the speed and scope of enforcement in ways that have caught many marketers off guard.

Ads can now be scanned and evaluated far more quickly and at far greater scale than any human review team could manage. That sounds efficient. In practice, the false positive rate has exploded. Campaigns that are fully compliant get flagged, not because they’re doing anything wrong, but because the AI is pattern-matching on signals that look suspicious out of context.

A few examples of what’s getting flagged:

Specific words and phrases. Terms like “symptoms,” “diagnosis,” “treatment options,” or even condition names used in an educational context can trigger automated rejections, even when the ad itself is clearly informational and compliant.

Microsites and redirect links. If your ad links to a microsite that redirects to another domain, AI systems may flag it as spam or a deceptive destination, and this gets more complicated when that destination involves appointment scheduling or medication information, both of which can read as conversion-oriented in ways that trigger additional flags.

Unindexed or thin landing pages. Platforms are also increasingly using AI to evaluate where your ad sends people. If your landing page isn’t properly indexed or doesn’t clearly signal what the site is and who it serves, the system may flag the ad for sending users somewhere it can’t evaluate.

Behavior intent signals. The deeper shift is behavioral. Meta’s algorithm was inferring health intent from behavioral signals: content engagement patterns, app usage, purchase history adjacent to health categories, without an advertiser ever selecting a condition from a targeting menu. The new restrictions target that inference layer specifically, beyond explicit condition targeting. That’s why campaigns that felt compliant are now underperforming.

And when something gets flagged incorrectly, the appeals process is its own ordeal. Requesting a manual review has become a cycle of hand-offs between departments. On two separate support chats, we were passed to more than six different people over a two-to-three-hour window, then told the conversation would move offline and we wouldn’t hear back in days, sometimes weeks. Meanwhile, the rest of your campaign is live in market, and you’re stuck waiting for a response, like someone digging through your bag while the flight is boarding and calling your name over the intercom.

What marketers can do now

All of these safeguards exist for real reasons. Patient privacy matters, and predatory health advertising is a genuine problem. We’re not arguing that the rules shouldn’t exist. But navigating them is now a core part of the job. Luckily, getting creative under tight parameters is kind of our thing.

So what does the modern marketer’s version of TSA PreCheck look like?

Diversify your platform mix. Relying on a single network, especially one as restricted as Meta has become for healthcare, is a structural risk. Depending on your client and audience, platforms like Reddit, Snapchat, LinkedIn, and TikTok offer targeting capabilities and audience segments that aren’t subject to the same restrictions. The right mix varies, but the principle holds: don’t build your program on a single foundation that can shift beneath you.

Create at scale. When you can’t target narrowly, let your ad speak for itself. Write ads that speak directly to a single condition, like spine pain. Then show that ad to a wide audience instead of a narrow one. People with spine pain will notice it. Others will scroll past. The message does the work that targeting used to do.

This means making more ads, one for each service line, instead of fewer. It also means testing your messages more carefully. This takes real time and effort. It’s not just a nice idea. It’s a real change in how the team works.

Retarget on high-intent engagement signals. Where pixel retargeting is off the table and no third-party tracking is available, you can still build audiences around in-platform engagement behavior: video view-throughs, post saves, content shares, lead form opens, ad click engagement, and message interactions. When patient Andy clicks and watches the full video about shoulder pain, we can now retarget him with blogs about shoulder pain management. These signals live entirely within the platform, don’t depend on health-category data, and hold up under the current restrictions.

Target the content, not the person. Placing an ad next to relevant editorial content, like an orthopedic ad on a health publisher’s article or a sports injury ad during a game broadcast, reaches the right audience without tracking anyone’s individual health status. Because no user-level health inference happens, this approach sidesteps the consumer-health-data problem entirely.

Make sure your landing pages are doing their job. Given how AI systems now evaluate ad destinations, your landing pages need to be properly indexed, clearly scoped, and transparent about what they’re asking users to do. If your page redirects users to another domain, for scheduling, a patient portal, or a partner site, say so explicitly. A clear disclosure (“You’ll be directed to [destination] to complete your request”) signals to both users and AI review systems that the handoff is intentional and above board. This is good practice regardless, but it’s now also a compliance consideration.

The travelers who move through airports most efficiently aren’t the ones complaining about the rules. They’re the ones who got PreCheck, packed smarter, and planned ahead for a system that had already changed.

That’s the posture healthcare marketers need now. The old infrastructure isn’t coming back, but the marketers who adjust their strategy, diversify channels, and identify engagement signals will move faster than those still stuck in general boarding.

If you’re not sure where your program stands or where to start, that’s exactly the kind of problem we were built to work through. Let’s talk.